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Medical literature suggests that antibiotics are 
frequently not appropriately prescribed and their use 
in everyday clinical practice is not based on an 
evidence centered approach.1,2 For instance, 
antibiotics are prescribed for viral fever and common 
cold, against which they are not effective. The chronic 
and inappropriate use of antibiotics leads to 
development of resistance. This development of 
bacterial resistance to antibiotics has been one of the 
most important challenges faced by medical 
professionals globally. Rational antibiotic therapy and 
patient information are important building blocks for 
maintaining the efficacy of these drugs, which are 
essential to modern medicine. It is however also 
important to consider other risks associated with 
antibiotic use. These include possible cardiovascular 
side effects and risks of antibiotic therapy as well as 
the risks resulting arising therefrom. Long-term use of 
antibiotics in middle-aged or older women may 
increase the risk of subsequent cardiovascular 
diseases.3 Possible causes include the following 
cardiac side effects or risks of antibiotics QT interval 
prolongation, risk of aortic aneurysms and dissection, 
adverse reactions due to clinically significant 
interactions with antibiotics.  
 
Prolongation of the QTc interval is probably the most 
therapeutically significant and best-documented side 
effect of therapy with certain classes of antibiotics, 
which  may  lead   to    life-threatening    polymorphic  
 
 
ventricular tachyarrhythmias, so-called torsades de 
pointes.4 Both fluoroquinolones and macrolides are 
associated with these side effects. Fluoroquinolones in 
general, and moxifloxacin in particular, have a direct 
effect on a specific potassium current which delays 
cardiac repolarization, reflected in a surface ECG as 
prolonged QT interval. This type of change in 
repolarization may result in the development of 
torsades de pointes in patients.  Fluoroquinolones are 
no longer the first choice in the treatment of 
infections due to medically significant side effects. 
They should only be used if other and better tolerated 
antibiotics are unavailable. Severe musculoskeletal 
side effects include tendinitis, tendon rupture, 
myalgia, muscle weakness, arthralgia, joint swelling 
and gait disorders. Severe side effects involving the 
peripheral and central nervous systems include 
peripheral neuropathy, sleeplessness, depression, 
fatigue, impaired memory as well as visual, auditory, 
olfactory and gustatory disorders. Special caution is 
generally advised in elderly patients, those with renal 
problems or following organ transplantation, as well 
as patients being concomitantly administered 
systemic corticosteroids. Macrolides are widely used 
class of antibiotics used in the treatment of many 
common infections. 
 
They are considered safe and are well tolerated in 
general. However, several studies have demonstrated 
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in recent years.1,2 Reported adverse cardiac events due 
to macrolides include QT interval prolongation, 
torsades de pointes, ventricular tachycardia, and 
sudden cardiac death. These have especially been 
observed in patients with pre-existing cardiovascular 
diseases. All macrolides in current use carry a risk of 
QTc interval prolongation and/or torsades de pointes. 
A few studies have demonstrated an association 
between administration of macrolide antibiotics and 
sudden cardiac death. The extent of difference of this 
risk between the various macrolides remains 
controversial. Thus, certain precautions and attention 
to risk factors are recommended for all active 
substances. These include cardiovascular diseases, 
long QT syndrome, electrolyte disturbances and 
pharmacokinetic interactions.5-16  
 
It is important to take these risk factors into account 
and monitor patients accordingly or avoid the use of 
QT prolonging drugs in such cases whenever possible. 
In principle, the combination of the two antibiotic 
groups with other drugs which may also induce 
significant QT prolongation and torsades de pointes is 
critical. This combination is recommended only under 
intensive observation or is contraindicated. In 
principle, the combination of two or more drugs 
which may potentially prolong the QTc interval or 
increase the risk of TdP should be avoided.4 Thus, in 
polypharmacy, the possibility of using a QT-neutral 
drug with the same therapeutic efficacy instead of a 
QT-prolonging drug should be evaluated in every 
patient and must be given preference. If combination 
therapy is unavoidable, then the lowest effective dose 
must be selected and administered under ECG 
monitoring. Fluoroquinolones may promote the 
degradation of collagen.  Predisposing factors for 
aortic aneurysms and dissection include: family 
history of aneurysm, pre-existing aortic aneurysm or 
aortic dissection, Marfan syndrome, vascular Ehlers-
Danlos syndrome, Takayasu arteritis, giant cell 
arteritis, Behçet’s disease, hypertension and 
atherosclerosis. Clarithromycin and erythromycin are 
potent CYP3A4 and P-glycoprotein inhibitors. 
Caution is advised in combination with drugs which 
are primarily metabolized by CYP3A4 or are good 
substrates for the transport protein P-gp due to the 
greater toxicity of these drugs. Concomitant 
administration of clarithromycin and calcium 
antagonists such as amlodipine and felodipine may 
lead to hypotension and acute kidney failure, with 
high mortality. Azithromycin is the drug of choice in  
 
such cases since it does not exhibit such 
pharmacokinetic interactions. The use of 
azithromycin is therefore recommended in 
polypharmacy.17  
 
Cotrimoxazole  is an important and potential trigger 
of hyperkalemia in elderly patients as well as in those 
with renal dysfunction, which is of particular 
significance during concomitant intake of ACE 
inhibitors or AT1 blockers. The trimethoprim 
component acts like the potassium-sparing diuretic 
amiloride. High cardiovascular mortality has been 
observed in combination with ACE inhibitors and 
angiotensin blockers.18 Changes in microbiomes and 
possible cardiovascular effects. The intestinal flora 
plays a key role in many physiological processes and 
pathological diseases. Every dose of the antibiotic 
affects the balance and composition of intestinal flora 
by alteration in the microbiome such as a possible 
reduction in the occurrence of probiotic bacteria. 
Findings from animal experiments suggest that 
exposure to antibiotics may also increase 
cardiovascular risk by alteration of the microbiome. 
Thus, intestinal bacteria, which enter serum via their 
metabolites and exhibit a protective effect against 
arteriosclerosis, may be reduced. Some antibiotics 
stimulate the proliferation and activity of 
macrophages in vitro, which may lead to 
accumulation of lipids and result in atherosclerosis in 
the long term. Recently conducted studies indicates 
an unexpected effect of antibiotics in furthering 
inflammation.19-25 
 
According to current recommendations, caution is 
advised while administering fluoroquinolones due to 
their side effects. These include cardiac toxicities and 
associated risks. The patient’s individual risk factors 
must be considered while administering macrolides 
and concomitant use with other QT-prolonging drugs 
must be avoided at any cost. The macrolides 
clarithromycin and erythromycin exhibit drug 
interactions and should be avoided whenever 
possible. Azithromycin is the macrolide of choice in 
polypharmacy. In general, effects on the microbiome 
must be considered while prescribing antibiotics. This 
may also result in cardiac toxicities or long-term risks 
according to initial reports. It is therefore imperative 
that antibiotics be administered in accordance with 
the given indication, with therapy targeted at the 
treatment of bacterial infections. Restricted use of 
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not only to the reduction of bacterial resistance, but 
also towards reduction of cardiovascular risks. 
 
CONCLUSION 
The frequent use of antibiotics for inappropriate 
indications leads to selection of resistant pathogens, 
promotion of their spread and development of 
resistance. Other risks associated with the use of 
antibiotics must be considered. These include possible 
cardiovascular side effects of antibiotic therapy as well 
as the risks resulting arising therefrom, and include 
prolongation of the QTc interval, the risk of aortic 
aneurysms and dissection, side effects due to clinically 
significant interactions and changes in microbiomes 
with resultant possible side effects and risks. 
According to the current recommendations, caution is 
advised while administering fluoroquinolones due to 
their side effects. The patient’s individual risk factors 
must be considered while administering macrolides 
and concomitant use with other QT-prolonging drugs 
must be avoided at any cost. Use of the macrolides 
clarithromycin and erythromycin which exhibit 
potent interactions should be avoided whenever 
possible. Azithromycin is the macrolide of choice in 
polypharmacy. In general, the effects on the 
microbiome must be considered when prescribing 
antibiotics. These may result in long-term 
cardiovascular risks based on initial reports. It is 
therefore imperative that antibiotics be administered 
in accordance with the given indication, with therapy 
targeted at the treatment of bacterial infections. 
Restricted use of antibiotics is therefore important 
since it contributes not only to the reduction of 
bacterial resistance, but also towards reduction of 
cardiovascular risks. This confirms the compelling 
need to use antibiotics in an indication-oriented and 
targeted manner for bacterial infections. The 
restrictive use of antibiotics is therefore not only 
important to reduce bacterial resistance but also 
contributes to the reduction of cardiovascular risks. 
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